Last reviewed · How we verify
NCT04927325
Erythema at Exit Site & Tablet Camera
NA trial testing Set of Photos in CLABSI - Central Line Associated Bloodstream Infection in 20 participants. Completed in 10 October 2022.
10 October 2022
Quick facts
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 30 June 2021 |
| Primary completion | 10 October 2022 |
| Estimated completion | 10 October 2022 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Set of Photos
Conditions studied
- CLABSI - Central Line Associated Bloodstream Infection — all drugs for CLABSI - Central Line Associated Bloodstream Infection →
- CRBSI - Catheter Related Bloodstream Infection — all drugs for CRBSI - Catheter Related Bloodstream Infection →
- Digital Technology — all drugs for Digital Technology →
Sponsor
Medical University of Vienna
Who can join
18 and older, any sex, with CLABSI - Central Line Associated Bloodstream Infection or CRBSI - Catheter Related Bloodstream Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: In critical care medicine central venous catheters play an important role in the source of infections. In the daily routine prior to the diagnosis the suspicion of catheter related infection is discussed in the medical team due to signs of systemic inflammation or exit site infection like erythema, induration or tenderness. However, if an erythema at exit site of a central line can be quantified with a tablet camera, is unknown. Methods: Standardized set of photos will be taken of 10 central lines with a reddened exit site and 10 catheters without an erythema (as a control over time) with a tablet camera and a single-lens reflex camera. The percentage of usable images between tablet and single-lens reflex camera will be analysed. Furthermore, two independent clinical experts from dermatology will grade blinded de-identied images on a scale from 0 to 4 (0 - no erythema, 1- very faint, 2 - faint, 3 - bright, 4 - very bright). Objectives: The primary objective of this feasibility study aims to analyze the reliability of a tablet camera as a device for quantification of erythema around an exit site.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04927325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CLABSI - Central Line Associated Bloodstream Infection
Currently open trials in the same condition.
- NCT07255105 — Epidemiological Investigation of Central Venous Catheter-related Bloodstream Infections in Icus in China · recruiting
- NCT06365528 — Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes · NA · recruiting
- NCT06085690 — Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science · NA · recruiting
Other Medical University of Vienna trials
Trials by the same sponsor.
- NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
- NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
- NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04927325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
- Last refreshed: 17 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04927325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing